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This study investigated the effects of polysaccharides from Enteromorpha prolifera (PEP) on glucose metabolism in a rat model of
diabetes mellitus (DM). PEP (0, 150, 300, and 600mg/kg) was administered intragastrically to rats for four weeks. After treatment,
fasting blood glucose (FBG) and insulin (INS) levels were measured, and the insulin sensitivity index (ISI) was calculated. The
morphopathological changes in the pancreas were observed. Serum samples were collected to measure the oxidant-antioxidant
status. The mRNA expression levels of glucokinase (GCK) and insulin receptor (InsR) in liver tissue and glucose transporter type
4 (GLUT-4) and adiponectin (APN) in adipose tissue were determined. Compared with the model group, the FBG and INS levels
were lower, the ISI was higher, and the number of islet 𝛽-cells was significantly increased in all the PEP groups. In the medium- and
high-dose PEP groups, MDA levels decreased, and the enzymatic activities of SOD and GSH-Px increased. The mRNA expression
of InsR and GCK increased in all the PEP groups; APN mRNA expression increased in the high-dose PEP group, and GLUT-4
mRNA expression increased in adipose tissue. These findings suggest that PEP is a potential therapeutic agent that can be utilized
to treat DM.
1. Introduction
Diabetes mellitus (DM) is characterized by endocrine-
induced metabolic disorders with complex etiology [1]. The
major pathophysiological issue for DMpatients is insufficient
insulin (INS) secretion associated with the destruction of
pancreatic islet 𝛽-cells and insulin resistance (IR), ultimately
resulting in complications in numerous systems, such as
the cardiovascular and renal systems [2, 3]. DM-associated
cardiovascular complications have the highest disability and
mortality rates and have caused the greatest damage of all the
chronic complications in China [4]. Until now, DM patients
had to consistently receive injections of exogenous INS or
take oral hypoglycemic drugs, and this long-term treatment
induces drug side effects and creates a significant economic
burden.Therefore, it is worth exploring diet composition and
nutritional status to prevent and/or identify therapies to treat
this chronic disease, as it is seldom studied.
Polysaccharides, which belong to a class of essential
organic compounds that form the base of all living creatures,
are generated by combining multiple monosaccharides of the
same type or of different types [5]. With advancements in
related research, the activity of marine algal polysaccharides
has become a hot research topic worldwide [6, 7]. Marine
algae are rich in polysaccharides, which account for more
than 50% of their dry weight. Studies have demonstrated
that marine algal polysaccharides are predominantly sulfated
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polysaccharides [8]; the antioxidant activity of sulfated glu-
cans is greater than that of regular glucans [9]. Previous
studies have shown that many marine algal polysaccharides,
including laminarin 13, exopolysaccharide of Porphyrid-
ium cruentum 18, Spirulina polysaccharides 22, and alginic
sodium diester 25, play a role in lowering blood sugar and
treating DM complications, such as hyperlipidemia [10–13].
However, different marine algal polysaccharides contain dif-
ferent functional agents; therefore, they may work to prevent
or treat DM by different mechanisms and further studies in
this area are warranted.
Enteromorpha prolifera belongs to the phylum Chloro-
phyta, class Chlorophyceae, order Ulvales, and genus Entero-
morpha. It is a large, natural wild green alga that grows in
offshore shoals and is widely distributed in rock pools in
river mouths and tidal zones. Enteromorpha prolifera has
been recognized as an edible andmedicinal alga since ancient
times. It is highly abundant, and currently, themajority grows
and dies without humanmanagement or control. Enteromor-
pha prolifera naturally has a strong reproductive capacity,
which can have a significant negative impact on the envi-
ronment and aquaculture [14]. The large-scale outbreak of
large green algae, such as Enteromorpha prolifera, is now
called “green tide,” which is considered to be a type of
marine disaster similar to red tide [15]. However, if these algae
could be utilized, then waste could be turned into a valuable
resource. Enteromorpha prolifera polysaccharides (PEP) are
soluble sulfated heteropolysaccharides. Previous studies have
demonstrated that PEP have numerous functional bioactiv-
ities, such as strong antibacterial, anti-inflammatory, antitu-
mor, and antioxidant functions, as well as the abilities to rein-
force immunity and regulate blood lipid levels [16–19]. How-
ever, whether PEP has an anti-DMpharmacological effect has
been seldom studied.
Based on these observations, the purpose of this study
was to determine the anti-DM effects of PEP in a rat model
of DM and investigate the possible underlying mechanisms.
Our study provides experimental evidence for the clinical
treatment of DM and the theoretical basis for the develop-
ment and application of PEP.
2. Material and Methods
2.1. Animals. Ninety six-week-old male Sprague-Dawley
(SD) rats weighting 90±10 gwere obtained from the Shanghai
SLAC Laboratory Animal Co. LTD. The experimental proto-
col was approved by the Animal Care and Use Committee of
FujianMedical University.The experimental procedureswere
carried out in accordance with international guidelines for
the care and use of laboratory animals.
2.2. High-Sugar, High-Fat Diet. A high-sugar, high-fat diet
was prepared based on the following formula that was
slightly modified from a previous study [20]: 65% basal feed,
20% sucrose, 10% lard, 2.5% egg yolk powder, and 2.5%
cholesterol. The basal feed was prepared and provided by the
Laboratory Animal Center of Fujian Medical University; the
main components were 30% corn, 21% soybean cake, 10%
bran, 28% wheat middlings, 9% fish powder, 1.7% CaHPO
4
,
0.3% salt, 1.5% yeast, and 1% fish liver oil.
2.3. Chemicals. PEP was extracted and prepared in our
laboratory from Enteromorpha prolifera that was collected
from the coastal region of Fujian, China, using the water
extraction-alcohol precipitation method. The obtained PEP
sample was a soluble polysaccharide. Streptozotocin (STZ)
was obtained fromSigmaChemicalCo. (St. Louis,MO,USA).
All other reagents were of analytical grade.
2.4. Experimental Design. After one week of acclimatization,
the rats were randomly divided into the control group of
ten rats and model groups of eighty rats. Then, the control
group was fed a normal diet, and the model group was
fed the above high-sugar, high-fat diet for four weeks. After
four weeks, the model group was injected intraperitoneally
with 30mg/kg streptozotocin (STZ) [21]; after 72 h, plasma
glucose levels were determined, and a glucose concentration
≥200mg/dL indicated that the hyperglycemic rat (DM)
model is established [22]. Subsequently, 50 successful DM
model rats were divided into five groups of ten rats each:
the model, metformin hydrochloride (metformin HC), and
low-, medium-, and high-dose PEP groups. The metformin
HC group received 500mg/kg metformin hydrochloride
intragastrically, and the low-, medium-, and high-dose PEP
groups were dosed intragastrically with PEP at 150mg/kg,
300mg/kg, and 600mg/kg (distilled water as the solvent),
respectively, once per day. The model and control groups
received equivalent distilled water intragastrically. The doses
of PEP used in this study were selected based on our previous
studies and in accordance with other previous reports [23,
24]. The intervention period was four weeks. At the end of
the intervention, the rats were fasted for 12 hours and then
sacrificed by decapitation, and the blood samples, perirenal
white adipose tissue, liver, and pancreatic tissue samples were
harvested and stored at −80∘C until use.
2.5. Characterization of Polysaccharides from Enteromorpha
prolifera. DEAE-cellulose and Sephadex-100 were used to
purify and separate the PEP. The structural characteristics
of PEP were observed using infrared spectrum analysis. The
compositions of the PEP monosaccharides were determined
by gas chromatographic analysis.
2.6. Fasting Blood Glucose (FBG) Measurements and the Oral
Glucose Tolerance Test (OGTT). After the rats were fasted
for 12 hours, the blood sample was collected and FBG was
determined on days 0, 7, 14, 21, and 28 after the intervention
treatment using a blood glucose meter on the caudal vein
[25]. After measuring the FBG on day 28, the rats in each
groupwere dosed intragastrically with a 50% glucose solution
(2 g/kg); the blood glucose levels after 0.5, 1, and 2 h were
measured for the OGTT [26].
2.7. Fasting Insulin (FINS) Measurements and the Insulin
Sensitivity Index (ISI). After the rats were fasted for 12 hours,
the blood sample was collected and the serum FINS levels
for all rats in each group were measured using the ELISA
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method. The ISI is the reciprocal of the product derived
from the multiplication of the FBG and INS levels. Because
this index demonstrated a skewed distribution, the natural
logarithm was used: ISI = Ln 1/(FBG × FINS) [27].
2.8. Determination of Serum Malondialdehyde (MDA), Super
Oxide Dismutase (SOD), and Glutathione Peroxidase (GSH-
Px). Malondialdehyde (MDA) content was assayed using
the TBA method of Buege and Aust [28]. SOD activity was
measured using the method of Misra and Fridovich [29].
Glutathione peroxidase (GPH-PX) activity was assayed using
the method of Rotruck et al. [30]. These biomolecules were
quantified using test kits that were obtained from theNanjing
Jiancheng Bioengineering Institute (Nanjing, China).
2.9. Histopathological Examination of the Pancreas. Pancre-
atic tissues were fixed in a 10% neutral formalin solution
for 24 h. After being washed overnight with running water,
the samples were embedded in paraffin, sectioned, baked,
and stained with hematoxylin and eosin (H&E). A specific
antibody against insulin/proinsulin was utilized to observe
the residual 𝛽-cells in islets by using immunohistochemical
method (IHC). The 𝛽-cells in islets were calculated as
integrated optical density per area (mean integrated optical
density) using the Image-ProPlus 4.5 image analysis software.
2.10. Detecting the mRNA Expression of Related Genes in
Adipose and Liver Tissue. The mRNA levels of GCK, InsR,
GLUT-4, and APN were determined using real-time PCR.
Total RNA was extracted from each sample (ten samples per
group) using the RNAiso Plus reagent (TaKaRa Biotechnol-
ogy Co., Ltd., Dalian, China) according to the manufacturer’s
instructions. RNA was reverse-transcribed into cDNA using
the PrimeScript Reverse Transcriptase Reagent (TaKaRa
Biotechnology Co., Ltd., Dalian, China) according to the
manufacturer’s instructions. Briefly, the following substrates
were placed into a tube: 2.0𝜇g of RNA in 2𝜇L, 1.0 𝜇L of 50𝜇M
oligo-dT primer, 1.0 𝜇L of PrimeScript RT Enzyme Mix,
1.0 𝜇L of 100𝜇M random hexamers, 5.0𝜇L of 5 x PrimeScript
Buffer, and 10.0 𝜇L of RNase-free dH
2
O, for a total volume of
20𝜇L. The mixture was incubated at 37∘C for 15min and at
85∘C for 5 sec. After reverse transcription, the samples were
stored at −20∘C until polymerase chain reaction (PCR) was
performed.
Real-time fluorescent quantitative PCR was carried out
with the SYBRGreen I fluorescent dye reagent (SYBR Premix
Ex Taq II, TaKaRa Biotechnology Co., Ltd.) and an ABI
System Sequence Detector 7500 (Applied Biosystems Inc.,
USA). 𝛽-actin was used as an internal standard to normalize
all samples for potential variations in mRNA content. Ampli-
fications were performed under the following conditions:
Stage 1, 95∘C for 30 sec, 1 cycle; Stage 2, 95∘C for 10 sec
and 60∘C for 34 sec, 40 cycles. The relative expression levels
of GCK, InsR, GLUT-4, and APN were normalized by the
internal standard𝛽-actin and expressed as a percentage of the
𝛽-actin value. The results are given as the mean ± standard
deviation. The oligonucleotide sequences of primers used



























2.11. Statistical Analysis. All data are expressed as the mean ±
standard deviation. The IBM SPSS 19.0 software was used
to analyze the data. Differences among the groups were
compared by a one-way ANOVA. An LSD test was used to
further analyze the differences between the two groups if
equal variances were assumed. If equal variances were not
assumed, Dunnett’s C test was used instead. A 𝑃 value of less
than 0.05 was considered significant.
3. Results
3.1. Characterization of Polysaccharides from Enteromorpha
prolifera. PEP was separated to four components, PEP-
1, PEP-2, PEP-3, and PEP-4, by DEAE-cellulose methods
(Figure 1(a)). PEP2 is the major component, at up to
81%. PEP-2 shows a single symmetric peak when it flows
through Sephadex-100 (Figure 1(b)). Infrared spectrum anal-
ysis shows that PEP-2 is a sulfate ester-containing polysaccha-
ride (Figure 1(c)). Gas chromatographic analysis shows that
the monosaccharides of PEP-2 were rhamnose, glucuronic
acid, arabinose, fucose, xylose, and glucose (Figures 1(d1)
and 1(d2)). The proportions of the monosaccharides are
5.12 : 1.32 : 3.38 : 1.62 : 1 : 1.03, respectively.
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Figure 1: Characterization of polysaccharides from Enteromorpha prolifera. (a) shows four peaks in the eluting curve, PEP-1, PEP-2, PEP-3,
and PEP-4. The peak area of PEP-2 is the largest and contains 161mg of polysaccharides. (b) shows the basic graph of PEP-2, which has a
single, symmetrical elution peak. (c) shows the wavenumbers of 3386.02 cm−1 as the stretching vibration of O–H, 2923.84 cm−1, 2853.28 cm−1,
and 1454.36 cm−1 as the vibration of –CH2–. The 1390.54 cm−1 and 1232.13 cm−1 symmetric stretching vibrations corresponded to two S=O
groups of sulfate groups. Furthermore, 848.09 cm−1 and 769.89 cm−1 are the antisymmetric and symmetric stretching vibrations of the sulfate
groups C–O and S–O. (d1) shows that the chromatogram of different standard monosaccharides. (d2) shows that PEP-2 is mainly composed
of rhamnose, glucuronic acid, arabinose, fucose, xylose, and glucose.
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Table 1: The effect of PEP on body weight, food consumption, and drinking water intake in DM rats.
Group Body weight (g) Food consumption (g/day/dam) Drinking water intake (mL/day/dam)
Control 517.75 ± 29.57∗ 11.26 ± 2.05∗ 15.21 ± 1.71∗
Model 359.12 ± 57.69# 9.85 ± 1.38# 34.18 ± 5.03#
Metformin HC 354.73 ± 58.61# 9.29 ± 1.71# 30.79 ± 5.83#
150mg/kg PEP 382.20 ± 40.36# 9.37 ± 2.26# 28.96 ± 8.39#
300mg/kg PEP 375.93 ± 43.58# 8.98 ± 1.63# 24.68 ± 5.29∗#
600mg/kg PEP 358.60 ± 35.08# 8.83 ± 1.69# 16.61 ± 2.82∗
A DM model was established by feeding rats a high-fat diet and injecting them with a low dose of STZ. After the model was established, PEP (150, 300, and
600mg/kg) was administered intragastrically for 28 d. The body weight, food consumption, and drinking water intake were measured. The data are presented
as the mean ± standard deviation (𝑛 = 10 rats). Compared with the model group: ∗𝑃 < 0.05; compared with the control group: #𝑃 < 0.05.
Table 2: The effect of PEP on FBG levels in DM rats.
Group FBG (mg/dL)
Day 0 Day 7 Day 14 Day 21 Day 28
Control 155.34 ± 35.1∗ 176.76 ± 38.52∗ 161.64 ± 27.18∗ 161.10 ± 29.88∗# 138.78 ± 28.62∗
Model 321.48 ± 46.1# 258.48 ± 35.82# 248.76 ± 39.60# 283.68 ± 37.98# 258.12 ± 58.68#
Metformin HC 328.86 ± 14.58∗ 148.32 ± 15.66∗ 151.38 ± 16.38∗# 153.18 ± 16.38∗# 150.48 ± 19.08∗#&
150mg/kg PEP 297.36 ± 40.86# 180.72 ± 19.62∗ 167.76 ± 41.40∗ 194.76 ± 34.02∗# 162.00 ± 33.30∗#&
300mg/kg PEP 291.42 ± 36.54# 159.48 ± 28.26∗ 152.28 ± 36.90∗ 172.08 ± 38.88∗ 149.04 ± 34.56∗&
600mg/kg PEP 325.08 ± 44.64# 175.14 ± 26.10∗ 160.74 ± 29.16∗ 173.34 ± 31.32∗ 158.76 ± 37.80∗&
A DM model was established by feeding rats a high-fat diet and injecting them with a low dose of STZ. After the model was established, PEP (150, 300, and
600mg/kg) was administered intragastrically for 28 d. Blood samples from the caudal vein were collected to determine FBG levels using a blood glucose meter.
The data are presented as the mean ± standard deviation (𝑛 = 10 rats). Compared with the model group: ∗𝑃 < 0.05; compared with the control group: #𝑃 <
0.05; compared with day 0: &𝑃 < 0.05.
3.2.The Effect of PEP on BodyWeight, Food Consumption, and
Drinking Water Intake in DM Rats. During the experiment,
gut dysfunction and death were not observed in DM rats.
However, body weight and daily food consumption were
significantly lower in the model group compared with the
control group (𝑃 < 0.05). On the contrary, the daily drinking
water intake was significantly higher than that in the control
group (𝑃 < 0.05). Compared with the model group, drinking
water intakes were lower in the medium- and high-dose PEP
groups (𝑃 < 0.05). Body weight and food consumption were
not significantly different between the low-, medium-, and
high-dose PEP groups, the metformin HC group, and the
model group (𝑃 > 0.05) (Table 1).
3.3. The Effects of PEP on FBG and OGTT in DM Rats.
Before the intragastric treatment (on day 0), the FBG was
significantly higher in the model, metformin HC, and PEP
groups than in the control group (𝑃 < 0.05). One week
after the intragastric intervention, the FBG levels decreased
in all groups; however, from weeks 1 through 4, rats in
the model group had a higher FBG than rats in the other
groups. After four weeks of intragastric treatment, the FBG
was lower in the PEP and metformin HC groups than in
the model group (𝑃 < 0.05). Compared with day 0, the
FBG levels in the low-, medium-, and high-dose PEP groups
and in the metformin HC group decreased (𝑃 < 0.05)
(Table 2). The OGTT indicated that the blood glucose levels
in all the rats peaked 30min after glucose injection and





























Figure 2:The effect of PEP on OGTT in DM rats. A DMmodel was
established by feeding rats a high-fat diet and injecting them with a
low dose of STZ. After the model was established, PEP (0, 150, 300,
and 600mg/kg) was administered intragastrically as an intervention
for 28 d (𝑛 = 10 rats). Subsequently, the OGTT was performed.
Control: control group; Model: model group; Mel HC: metformin
HC group; LPEP: low-dose PEP group; MPEP: medium-dose PEP
group; HPEP: high-dose PEP group.
group, the blood glucose levels recovered faster in the PEP
and metformin HC groups, but the differences between the
PEP groups were not significant (Figure 2).
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(a) Control (b) Model (c) Metformin HC
(d) 150mg/kg (e) 300mg/kg (f) 600mg/kg
Figure 3: The effect of PEP on the histopathological structure of the pancreas in DM rats (H&E staining). A DM model was established by
feeding rats a high-fat diet and injecting them with a low dose of STZ. After the model was established, PEP (0, 150, 300, and 600mg/kg)
was administered intragastrically as an intervention for 28 d (𝑛 = 10 rats). The pancreatic tissues were collected, embedded, sectioned, and
stained with H&E. (a) control: control group; (b) model: model group; (c) metformin HC: metformin HC group; (d) 150mg/kg: low-dose
PEP group; (e) 300mg/kg: medium-dose PEP group; (f) 600mg/kg: high-dose PEP group.
Table 3: The effect of PEP on FINS levels and the ISI in DM rats.
Group FINS (mU/L) ISI
Control 3.27 ± 0.20∗ −3.05 ± 0.30∗
Model 3.63 ± 0.25# −3.87 ± 0.32#
Metformin HC 3.39 ± 0.27∗ −2.92 ± 0.13∗
150mg/kg PEP 3.55 ± 0.29 −3.33 ± 0.32∗#
300mg/kg PEP 3.59 ± 0.15 −3.18 ± 0.31∗
600mg/kg PEP 3.39 ± 0.23∗ −3.21 ± 0.44∗
A DM model was established by feeding rats a high-fat diet and injecting
them with a low dose of STZ. After the model was established, PEP (150,
300, and 600mg/kg) was administered intragastrically as an intervention for
28 d. Blood samples from angular vein were collected to measure the FBG
and FINS levels with the ELISA kit, and the ISI was calculated. The data are
presented as the mean ± standard deviation (𝑛 = 10 rats). Compared with
the model group: ∗𝑃 < 0.05; compared with the control group: #𝑃 < 0.05.
3.4. The Effect of PEP on Serum FINS Levels and the ISI in
DM Rats. At the end of the experiment, FINS levels were
higher and the ISI was significantly lower in the model group
compared with the control group (𝑃 < 0.05). Compared with
themodel group, FINS levels were lower in the high-dose PEP
and the metformin HC groups (𝑃 < 0.05). The ISI was lower
in the low-, medium-, and high-dose PEP andmetforminHC
groups than in the model group (𝑃 < 0.05) (Table 3).
3.5.TheEffect of PEP on SerumMDALevels and the Enzymatic
Activity of SOD andGSH-Px in DMRats. Comparedwith the
control group, the MDA levels were higher and the GSH-Px
activity was lower in the model group (𝑃 < 0.05); although
there were no significant differences in SOD enzymatic
activity (𝑃 > 0.05), it exhibited a decreasing trend. Compared
with the model group, the MDA levels in the low-, medium-,
and high-dose PEP and metformin HC groups were lower
(𝑃 < 0.05).TheSODenzymatic activity in the low-,medium-,
and high-dose PEP groups increased. The GSH-Px activity
increased in themedium- and high-dose PEP andmetformin
HC groups (Table 4).
3.6. The Effect of PEP on the Histopathological Changes in
the Pancreas in DM Rats. Light microscopy following H&E
staining indicated that the pancreatic acini and islets were
intact in the control group. In themodel group, the islets were
scattered, the islet volume was significantly decreased, most
islet cells were atrophic and more lightly stained, there were
fewer cells, the cytoplasm was significantly decreased, the
nuclei exhibited large-scale condensation, and lymphocytic
filtration was extensive around and invading into the islets.
In themetforminHC group, themorphological changes were
not as severe as those in the model group. In the medium-
and high-dose PEP groups, the number of islets and 𝛽-cells
was significantly increased, the morphology and structure
were essentially normal, the cytoplasm was homogenous and
in greater quantity, the nucleoli were clear, and occasionally
a small amount of lymphocytic infiltration was observed
(Figure 3).
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Table 4: The effect of PEP on MDA, SOD, and GSH-Px in DM rats.
Group MDA (nmol/mL) SOD (U/mL) GSH-Px (𝜇mol/L)
Control 5.09 ± 0.63∗ 252.68 ± 24.92∗ 4800.00 ± 449.46∗
Model 5.94 ± 0.89# 243.45 ± 19.32 3680.00 ± 388.65#
Metformin HC 5.05 ± 0.51∗ 239.90 ± 28.09 4164.57 ± 589.16∗#
150mg/kg PEP 5.03 ± 0.45∗ 271.31 ± 23.37∗ 3979.43 ± 397.13#
300mg/kg PEP 4.25 ± 0.67∗# 272.63 ± 22.25∗ 4132.57 ± 483.74∗#
600mg/kg PEP 4.56 ± 0.96∗ 269.09 ± 26.05∗ 4304.00 ± 341.72∗#
A DM model was established by feeding rats a high-fat diet and injecting them with a low dose of STZ. After the model was established, PEP (150, 300, and
600mg/kg) was administered intragastrically as an intervention for 28 d. Blood samples from angular vein were collected to quantitate the enzymatic activity
of MDA (nmol/mL), SOD (U/mL), and GSH-Px (𝜇mol/L) in serum. The data are presented as the mean ± standard deviation (𝑛 = 10 rats). Compared with
the model group: ∗𝑃 < 0.05; compared with the control group: #𝑃 < 0.05.
The immunohistochemistry results indicated that, in the
pancreatic islets, the positively stained cells containing cyto-
plasmic bright red granules were𝛽-cells. In the control group,
the islets were predominantly round or oval with different
sizes, defined edges, and intact morphology; the islets were
full of copious bright red granules, and the staining was dark.
In the model group, the islet structure was damaged, the
edges were irregular, the islet area was decreased, there were
significantly fewer bright red granules, and the staining was
light. Compared with the model group, islets with darker
staining were present in the metformin HC group, and there
were significantly more bright red granules; similar results
were observed for the low-, medium-, and high-dose PEP
groups (Figure 4(a)). The mean integrated optical density of
𝛽-cells in islets was significantly lower in the model group
compared with the control group (𝑃 < 0.05). Compared
with the model group, the mean integrated optical densities
of 𝛽-cells were significant increased in the low-, medium-,
and high-dose groups (𝑃 < 0.05). However, the differences
between the model group andmetforminHC group were not
significant (Figure 4(b)).
3.7. The Effect of PEP on the mRNA Expression of GCK and
InsR in Liver Tissue and of APN and GLUT-4 in Adipose
Tissue in DM Rats. Compared with the model group, InsR
mRNA expression in the liver in the low-, medium-, and
high-dose PEP groups significantly increased (𝑃 < 0.05), and
GCK mRNA expression in the liver in the low-, medium-,
and high-dose PEP and the metformin HC groups increased
(𝑃 < 0.05). APN mRNA expression in adipose tissue was
higher in the high-dose PEP group than in the model group
(𝑃 < 0.05). GLUT-4 mRNA expression in adipose tissue in
the low-, medium-, and high-dose PEP and the metformin
HC groups was not significantly different from that in the
model group (𝑃 > 0.05), but GLUT-4 expression exhibited an
increasing trend wherein the expression level increased with
increasing PEP concentration (Figure 5).
4. Discussion
The etiology of DM is complex. It is primarily considered
to result from a combination of genetic factors and various
environmental factors [31]. There is no drug or method for
the prevention or treatment of DM that has a significant
therapeutic effect, few toxic side effects, and an acceptable
safety profile [32–34]. Therefore, studying nutritious com-
pounds that have minimal toxic side effects and can have
long-term use is important for the prevention and treatment
of DM.
Due to the different adsorption capacities of polysac-
charides by the DEAE cellulose method and the different
retention capabilities of polysaccharides by the Sephadex-100
gelmethod, we separated and highly purified polysaccharides
from Enteromorpha prolifera. By infrared spectrum analysis,
the main components of the polysaccharides were carbohy-
drates, which not only are rich in sulfate esters but also con-
tain ether compounds and unsaturated carbon chains, which
is in accord with previous studies [35]. The sulfate content
of polysaccharides from Enteromorpha prolifera was 19.2% in
our study, whichwas higher than that of previous studies [35].
Gas chromatographic analysis showed that the monosac-
charides of PEP were rhamnose, glucuronic acid, arabinose,
fucose, xylose, and glucose, which is inconsistent with a pre-
vious study in which galactose and mannose were observed
[35]. The discrepancies in these results may be due to differ-
ences in the species, origin, and season of Enteromorpha.
High blood glucose levels, hyperinsulinemia (in the early
stages), and low insulin sensitivity are the salient features of
DM. Impaired glucose tolerance (IGT) occurs in the middle
of the transition from normal to DM and is a primary feature
of glucose metabolic disorders. The mechanism by which
IGT occurs may be associated with IR and impaired islet
𝛽-cell function [36]. The rapid changes in glucose tolerance
and/or blood sugar levels are prone to induce DM; therefore,
OGTTs and blood glucose levels can be utilized to monitor
and control the occurrence anddevelopment ofDM[37].This
study confirmed that PEP reduced blood glucose levels in
DM rats and significantly improved IGT with similar effects
as the hypoglycemic agent metformin HC; in particular,
prominent effects were observed in the medium-dose PEP
group. Serum insulin levels were significantly reduced in the
high-dose PEP group, and insulin sensitivity was significantly
higher in all the PEP intervention groups. Furthermore, PEP
intervention alleviated the diabetes symptom of drinking
more water without changing caloric intake and inducing
gut dysfunction for food consumption and body weight
had no changed. These results indicated that PEP affected
the regulation of glucose metabolism by improving IGT,
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Figure 4: The effect of PEP on the histopathological structure of the pancreas in DM rats (IHC). A DM model was established by feeding
rats a high-fat diet and injecting them with a low dose of STZ. After the model was established, PEP (0, 150, 300, and 600mg/kg) was
administered intragastrically as an intervention for 28 d (𝑛 = 10 rats). The pancreatic tissues were collected, embedded, and sectioned, and
a specific antibody against insulin/proinsulin was utilized to observe the residual 𝛽-cells in islets by using immunohistochemical method
(IHC). (A) control: control group; (B) model: model group; (C) metformin HC: metformin HC group; (D) 150mg/kg: low-dose PEP group;
(E) 300mg/kg:medium-dose PEP group; (F) 600mg/kg: high-dose PEP group.The arrow indicates islet tissue. (a) shows the histopathological
structure of the pancreas in DM rats by IHC; (b) shows the mean integrated optical density of 𝛽-cells in islets in DM rats using the Image-Pro
Plus 4.5 image analysis software.
promoting insulin secretion by islet 𝛽-cells, and enhancing
insulin sensitivity.
High glucose can cause the nonenzymatic oxidation of
proteins and induce oxidative stress [38]. Chronic exposure
to high glucose levels increases the oxidation of glucose
itself, which produces enediol and dihydroxy compounds
as well as a significant amount of ROS [39]. Therefore, in
the model used in the study, the high-glucose, high-fat diet
that was fed to the rats stimulated oxidative stress; moreover,
in combination with the STZ injection that damaged the
pancreas, the oxidative damage in the pancreas as well as liver
was exacerbated, resulting in DM. SOD is a key intracellular
antioxidant that removes superoxide anion radicals in the
body [40]. GSH-Px is a scavenger that protects the structure
and functional integrity of the cell membrane by reducing
hydrogen peroxide and lipid hydroperoxides [41]. MDA
levels reflect the degree of lipid peroxidation in the body
and indirectly reflect the degree of cellular damage [42].


























































Figure 5: The effect of PEP on the mRNA expression of GCK and InsR in the liver and APN and GLUT-4 in adipose tissue in DM rats. A
DMmodel was established by feeding rats a high-fat diet and injecting them with a low dose of STZ. After the model was established, PEP (0,
150, 300, and 600mg/kg) was administered intragastrically as an intervention for 28 d. Subsequently, liver and adipose tissue was collected;
mRNAwas extracted, reverse transcribed into cDNA, and analyzed by real-time PCR to determine the mRNA expression levels in the rats in
each group.ThemRNA expression levels were determined using the relative quantificationmethod (𝛽-actin was used as the internal control).
The data are presented as the mean ± standard deviation (𝑛 = 10 rats). Compared with the control group: ∗𝑃 < 0.05; compared with the
model group: #𝑃 < 0.05.
In this study, compared with the control group, MDA levels
increased, GSH-Px activity decreased, and SOD activity
exhibited a decreasing trend in the model group, indicating
that there was more severe oxidative damage in the DM
rats, potentially attributable to the oxidative stress induced
by the high-sugar, high-fat diet and STZ. After four weeks
of PEP intervention, MDA levels significantly decreased and
SOD and GSH-Px activities increased in a dose-dependent
manner in all the PEP treatment groups compared with the
model group.These results indicated that PEP inhibited lipid
peroxidation in the cell membrane, relieved cellular oxidative
damage, and promoted the functional recovery of tissues by
enhancing antioxidant activity and promoting the clearance
of free radicals and peroxidation products, such as MDA.
The pathological examination of the pancreas revealed
that the number of pancreatic islet cells in the rats in the
high- and medium-dose PEP groups significantly increased
compared with the model group, whereas low-dose PEP
had a slightly weaker effect. The cellular morphology of the
pancreatic islet cells was nearly normal in the rats in the
high- and medium-dose PEP groups. This result confirmed
that PEP facilitated the repair of tissue damage and exerted a
protective function in the pancreas.
It is currently understood that insulin acts by interacting
with the InsR on the cell membrane (predominantly in hepa-
tocytes, adipocytes, and muscle cells) and that its functions
rely on receptor density and affinity in the cell membrane.
Therefore, InsR is the first key point of action for insulin,
and the InsR gene is critical for studies of IR [43]. Our study
demonstrated that mRNA level of InsR was significantly
higher in the low-, medium-, and high-dose PEP groups than
that in the model group; this result was consistent with the
majority of previous studies that have reported a reduction in
both the number and affinity for insulin of membrane InsR
in liver and muscle tissue of DM rats with IR [44]. The blood
sugar and insulin levels in the model group remained high,
indicating that PEP reversed IR by upregulating the number
of InsR. Further studies are needed to elucidate the precise
mechanisms.
GCK is a key enzyme in the regulation of glucose
metabolism and insulin secretion and is the first rate-limiting
enzyme in glycolysis. It catalyzes the phosphorylation of
glucose to glucose-6-phosphate, and this process is a pre-
requisite for liver glycogen synthesis. The functional loss or
decreased expression of GCK suppresses glucose utilization
in the liver and decreases insulin secretion from islet 𝛽-
cells. Studies have reported that GCK is critical for beta cell
hyperplasia under the condition of high-fat diet-induced IR
[45]. Therefore, mutations in the GCK gene may be a cause
of DM. Conversely, enhancing GCK gene expression may
have a therapeutic effect on DM. Our study demonstrated
that significantly higher GCKmRNA expression levels in the
livers of rats in the low-,medium-, and high-dose PEP groups
compared with those in the model group; the difference of
GCK mRNA expression levels between the high-dose group
and the metformin HC group was most dramatic. Previous
study showed that dietary phenolic compounds altered glu-
cose metabolism and decreased the risk of type 2 diabetes by
increasing the level of glucokinase mRNA [46]. Therefore, it
is possible that PEP improved glucosemetabolism inDM rats
by upregulating GCK mRNA expression.
GLUT-4 is a glycoprotein of 509 amino acids that
is highly expressed in insulin-sensitive tissues, including
muscle, adipose, and liver. These tissues also have high
levels of glucose uptake and utilization; these processes are
regulated by blood glucose and insulin [47]. Transmembrane
glucose transport is mediated by GLUT-4. Under resting
conditions, 90% of GLUT-4 molecules are distributed on the
inner cell membrane, and only a small portion is on the
outer cell membrane. When the insulin stimulation signal is
transmitted into cells, GLUT-4 translocates from the inner to
the outer membrane, therefore increasing glucose transport
[48]. When GLUT-4 function is impaired, glucose uptake as
well as utilization in peripheral tissues decreases, particularly
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in skeletal muscle and adipose tissue, leading to postreceptor
IR. Therefore, GLUT-4 dysfunction is a major contributor to
the onset of DM [49]. This study determined that GLUT-
4 mRNA expression in adipose tissue decreased in the rat
models; despite the fact that the differences between the
intervention groups and the model group were not signifi-
cant, PEP intervention induced GLUT-4 mRNA expression
to various extents. Previous study showed that the alterations
in GLUT-4 mRNA level in adipose tissue contributed to the
physiological activities of n-3 PUFA in preventing body fat
accumulation and in regulating glucose metabolism in rats
[50]. Therefore, it is possible that PEP improved glucose
metabolism by upregulating the GLUT-4 mRNA expression.
APN, also termed Acrip30/AMP1/GBP28, is a cytokine
that is secreted by adipocytes. APN is composed of 247
amino acids; the APN gene is located on 3q27 and encodes
susceptibility genes for DM and metabolic syndrome [51].
APN is a protective factor for IR, and therefore it is highly
correlated with insulin sensitivity and plays an important
role in IR. Similar to insulin, APN promotes glucose and fat
utilization and energy consumption in muscle and inhibits
gluconeogenesis and the synthesis of fatty acids and choles-
terol in the liver [52]. APN is predominantly expressed in
adipocytes, and the APN gene is only expressed in white
adipose tissue; therefore, changes in adipocyte number can
affect APN expression. It has been demonstrated in animal
models that injecting APN into lipoatrophic mice partially
reversed IR [53] and that the ability to control blood sugar lev-
els with insulin in transgenic rats with high APN expression
significantly increased [54]. In humans, the direct injection
of APN reduces blood sugar levels [55], and increased APN
increases insulin sensitivity in obese, DM, and IR patients.
Therefore, adipocytokines, such as APN, reach target organs
via various pathways to induce IR-related diseases, and
the downregulation of related factors might prevent IR by
improving insulin sensitivity. In this study, we determined
that the difference in APN gene expression between the high-
dose PEP group and themodel groupwas significant, whereas
APN gene expression was higher in the low- and medium-
dose PEP groups than in the model group but did not reach
significance. These results indicated that PEP improved IR
and enhanced insulin sensitivity by upregulating APN gene
expression in rat white adipose tissue and that it therefore has
potential for the prevention of DM.
Previous study had showed that Enteromorpha compressa
and polysaccharide fraction from Enteromorpha prolifera
exhibit potent antioxidant activity [17, 18]. These studies
indicate that PEP might directly exhibit antioxidant activity
to alleviate oxidative damage in the pancreas, and finally
improve glucose metabolism. However, PEP might improve
glucose metabolism by upregulating the InsR, GCK, APN,
and GLUT-4 mRNA expression in our present study, which
may alleviate oxidative damage for high glucose, ultimately
result in nonenzymatic oxidation of proteins, and induce
oxidative stress [38]. Therefore, in our present study, it is
unclear whether the improvements in glucose drive the
improvements in oxidative measures or vice versa. Further
work, especially in vitro study, in this area is warranted.
5. Conclusion
Our results indicate that PEP can improve glucose meta-
bolism in DM rats.Themechanismmay relate to the antioxi-
dant activity of PEP and its ability to regulate the mRNA level
of InsR, GCK, APN, and GLUT-4 gene in liver and adipose
tissue. These findings may suggest that PEP could be useful
for the therapy of diabetes mellitus.
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Kvetňanský, and Z. Zukowska, “Chronic stress, combined
with a high-fat/high-sugar diet, shifts sympathetic signaling
toward neuropeptide Y and leads to obesity and the metabolic
syndrome,” Annals of the New York Academy of Sciences, vol.
1148, pp. 232–237, 2008.
[21] X. Xiang, Z. Wang, Y. Zhu, L. Bian, and Y. Yang, “Dosage of
streptozotocin in inducing rat model of type 2 diabetes mel-
litus,” Wei Sheng Yan Jiu, vol. 39, no. 2, pp. 138–142, 2010
(Chinese).
[22] R. Li, T. Liang, L. Xu, Y. Li, S. Zhang, and X. Duan, “Protective
effect of cinnamon polyphenols against STZ-diabetic mice fed
high-sugar, high-fat diet and its underlying mechanism,” Food
and Chemical Toxicology, vol. 51, no. 1, pp. 419–425, 2013.
[23] J. Wei, S. Wang, G. Liu et al., “Polysaccharides from Entero-
morpha prolifera enhance the immunity of normal mice,”
International Journal of Biological Macromolecules, vol. 64, pp.
1–5, 2014.
[24] W. T. Lin and D. D. Liao, “Effects of enteromorpha’s polysac-
charide on lipid metabolism and adiponectin gene expression
in type 2 diabetic rats,” Acta Nutrimenta Sinica, vol. 35, pp. 181–
185, 2013 (Chinese).
[25] G. S. Dhatt, M. M. Agarwal, Y. Othman, and S. C. Nair,
“Performance of the roche accu-chek active glucose meter to
screen for gestational diabetes mellitus using fasting capillary
blood,”Diabetes Technology andTherapeutics, vol. 13, no. 12, pp.
1229–1233, 2011.
[26] J. Codina, M. Vall, and E. Herrera, “Comparative changes with
age of the fasting response in circulating ketone bodies, glucose
and insulin and oral glucose tolerance test in the rat,” Com-
parative Biochemistry and Physiology, Part A: Physiology, vol.
71, no. 2, pp. 231–236, 1982.
[27] M.Gutt, C. L. Davis, S. B. Spitzer et al., “Validation of the insulin
sensitivity index (ISI0,120): comparison with other measures,”
Diabetes Research and Clinical Practice, vol. 47, no. 3, pp. 177–
184, 2000.
[28] J. A. Buege and S. D. Aust, “Microsomal lipid peroxidation,”
Methods in Enzymology, vol. 52, pp. 302–310, 1978.
[29] H. P.Misra and I. Fridovich, “The role of superoxide anion in the
autoxidation of epinephrine and a simple assay for superoxide
dismutase,”The Journal of Biological Chemistry, vol. 247, no. 10,
pp. 3170–3175, 1972.
[30] J. T. Rotruck, A. L. Pope, H. E. Ganther, A. B. Swanson, D. G.
Hafeman, and W. G. Hoekstra, “Selenium: biochemical role as
a component of glutathione peroxidase,” Science, vol. 179, no.
4073, pp. 588–590, 1973.
[31] D. Asbury and A. E. Kalderon, “Etiology of insulin-dependent
diabetes mellitus: a review of the current literature,”The Journal
of the Arkansas Medical Society, vol. 79, no. 8, pp. 281–285, 1983.
[32] C. Zou and H. Hu, “Use of pioglitazone in the treatment of
diabetes: effect on cardiovascular risk,”Vascular Health and Risk
Management, vol. 9, no. 1, pp. 429–433, 2013.
[33] S. A. Stein, E. M. Lamos, and S. N. Davis, “A review of the
efficacy and safety of oral antidiabetic drugs,” Expert Opinion on
Drug Safety, vol. 12, no. 2, pp. 153–175, 2013.
[34] M. S. Islam and R. D. Wilson, “Experimentally induced rodent
models of type 2 diabetes,” Methods in Molecular Biology, vol.
933, pp. 161–174, 2012.
[35] B. Li, S. Liu, R. Xing et al., “Degradation of sulfated polysac-
charides from Enteromorpha prolifera and their antioxidant
activities,” Carbohydrate Polymers, vol. 92, no. 2, pp. 1991–1996,
2013.
[36] A. Kazemnejad, Z. Batvandi, and J. Faradmal, “Comparison
of artificial neural network and binary logistic regression for
determination of impaired glucose tolerance/diabetes,” Eastern
Mediterranean Health Journal, vol. 16, no. 6, pp. 615–620, 2010.
12 Journal of Diabetes Research
[37] E. Bartoli, G. P. Fra, and G. P. C. Schianca, “The oral glucose
tolerance test (OGTT) revisited,” European Journal of Internal
Medicine, vol. 22, no. 1, pp. 8–12, 2011.
[38] T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing
mitochondrial superoxide production blocks three pathways of
hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp. 787–
790, 2000.
[39] T. J. Guzik, S. Mussa, D. Gastaldi et al., “Mechanisms of
increased vascular superoxide production in human diabetes
mellitus: role of NAD(P)H oxidase and endothelial nitric oxide
synthase,” Circulation, vol. 105, no. 14, pp. 1656–1662, 2002.
[40] H. Yamamoto, P. Zhao, and K. Inoue, “Origin of two isoprenoid
units in a lavandulyl moiety of sophoraflavanone G from
Sophora flavescens cultured cells,” Phytochemistry, vol. 60, no.
3, pp. 263–267, 2002.
[41] J. Q. Wu, T. R. Kosten, and X. Y. Zhang, “Free radicals, antiox-
idant defense systems, and schizophrenia,” Progress in Neuro-
Psychopharmacology and Biological Psychiatry, vol. 46, pp.
200–206, 2013.
[42] D. C. Wallace, “Animal models for mitochondrial disease,”
Methods in Molecular Biology, vol. 197, pp. 3–54, 2002.
[43] R. Mioni, B. Mozzanega, M. Granzotto et al., “Insulin receptor
and glucose transporters mRNA expression throughout the
menstrual cycle in human endometrium: a physiological and
cyclical condition of tissue insulin resistance,” Gynecological
Endocrinology, vol. 28, no. 12, pp. 1014–1018, 2012.
[44] G. Sesti, M. Federici, D. Lauro, P. Sbraccia, and R. Lauro,
“Molecular mechanism of insulin resistance in type 2 diabetes
mellitus: role of the insulin receptor variant forms,” Diabetes/
Metabolism Research and Reviews, vol. 17, no. 5, pp. 363–373,
2001.
[45] Y. Terauchi, I. Takamoto, N. Kubota et al., “Glucokinase and
IRS-2 are required for compensatory 𝛽 cell hyperplasia in
response to high-fat diet-induced insulin resistance,” Journal of
Clinical Investigation, vol. 117, no. 1, pp. 246–257, 2007.
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